Nutra Pharma Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022

Nutra Pharma Corp. is a holding company, which owns intellectual property and operates in the biotechnology industry. The Company conducts drug discovery research and development activities on its own and through its subsidiary, ReceptoPharm, Inc. Its first consumer product, Cobroxin, is an over-the-counter pain reliever designed to treat moderate to severe chronic pain. Its second consumer product, Nyloxin, is an over-the-counter pain reliever that is a stronger version of Cobroxin and is designed to treat severe chronic pain. Pet Pain-Away is an over-the-counter pain reliever designed to treat pain in cats and dogs. Equine Pain-Away is an over-the-counter topical pain reliever designed to treat pain and inflammation in horses. Its Luxury Feet is an over-the-counter pain reliever designed specifically to treat foot pain and inflammation, especially for women who wear high heels and stilettos. The Company also manufactures Cell Defender, ZMUNITY, and Avini Plus Energy, among others.